pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Dermatology · news · pharmadog
← back to Dermatology
News · Dermatology
226
stories
1d
AstraZeneca, Calidi, Tempest make significant workforce cuts
biospace
2d
Aclaris drops TSLP program from pipeline after flunking phase 2 eczema test
fiercebiotech
2d
Deaths, failed trials and other recent setbacks in the autoimmune space
biospace
5d
Opinion: New organ donation rules are unfair to families
stat
6d
Game Changer Products LLC Issues Voluntary Nationwide Recall of 10 Day Forecast Capsules Due to the Presence of Undeclared Sildenafil and Acetaminophen
fda recalls
7d
AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning
biopharma dive
9d
J&J and Protagonist’s Icotyde improves psoriatic arthritis but AbbVie’s Skyrizi likely to reign
biospace
9d
STAT+: Gene therapy’s long-debated cancer risk materializes
stat
9d
Zura reports Phase 2 flop in painful skin disorder, stock nosedives
endpoints
12d
‘Cancer hasn't seen this molecule before’: Onchilles’ injection shows potential for solid tumors
fiercebiotech
12d
Eugia US LLC (f/k/a Auro Medics Pharma LLC) Issues Voluntary Nationwide Recall of Vancomycin Hydrochloride for Injection USP 1.25g/Vial-30mL (Single Dose Vial) Due to Presence of Particulate Matter
fda recalls
16d
China's InventisBio delivers competitive TYK2 data in phase 3 psoriasis win
fiercebiotech
19d
FDA Approves First Plasmid DNA-based Immunotherapy for Adults with Recurrent Respiratory Papillomatosis
fda press
19d
Aspen raises a $141M IPO in pursuit of a cell therapy for Parkinson’s
biopharma dive
20d
Opinion: Health care needs buyers willing to say no
stat
22d
Parkinson’s-focused Aspen and bispecific biotech Bambusa both shoot for $134M IPOs
fiercebiotech
25d
Opinion: STAT readers on Elizabeth Holmes, cancer screening, and more
stat
25d
‘It is what it is’: Merck exec unruffled by ‘unfortunate’ leak of ESMO cancer vaccine data
fiercebiotech
26d
STAT+: Treasury proposes major restrictions to U.S. investment in Chinese biotech sector
stat
26d
STAT+: AI drug firm Pathos raises $237 million, pushing valuation to $3 billion
stat
26d
STAT+: Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer
stat
26d
STAT+: Alnylam says Huntington’s drug shows promise in early study
stat
27d
AbbVie’s skin disease drug lessens abscess burden in Phase 3 but falls below expectations
biospace
27d
STAT+: Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial
stat
27d
STAT+: AbbVie skin disorder drug succeeds in late-stage trial, but results miss market expectations
stat
27d
AbbVie notches Phase 3 win in painful skin condition, FDA filing likely next year
endpoints
27d
AbbVie scratches out phase 3 hidradenitis suppurativa win but falls short of expectations
fiercebiotech
27d
Roivant's TYK2/JAK inhibitor reduces need for steroids in inflammatory eye disease
biospace
28d
Roivant, continuing ascent, claims another victory for rare disease drug
biopharma dive
28d
Drug prices climb past $250K as US patients balk at the pharmacy
biospace
← prev
page 1 of 8
next →